{"title":"丙戊酸和左乙拉西坦对胶质瘤患者生存的影响：一项荟萃分析研究。","authors":"Arya Shirani, Mobin Obeidinia, Makan Ziafati, Javad Garavand, Moazzameh Ramezani, Fatemeh Ramezani","doi":"10.1097/CAD.0000000000001746","DOIUrl":null,"url":null,"abstract":"<p><p>In this meta-analysis study, the effect of valproate (VPA) and levetiracetam (LEV) on the survival of glioma patients taking temozolomide (TMZ) was investigated. The cumulative hazard ratios (HR) of overall survival (OS) and progression-free survival from published clinical studies were determined using a random effects model to estimate the strength of the association between VPA/LEV and survival in glioma patients. The results showed that VPA (data from 2304 patients from 14 clinical trial studies) and LEV (data from 1610 patients from 11 clinical trial studies) increase OS by 20% [HR = 0.80; 95% confidence interval (CI), 0.69-0.94; P = 0.01] and 18% (HR = 0.82; 95% CI, 0.68-0.98; P = 0.03), respectively. Use of VPA and LEV as anticonvulsant drugs increased the OS of patients with glioma taking TMZ to an almost equal extent. These findings need to be confirmed in larger prospective studies.</p>","PeriodicalId":7969,"journal":{"name":"Anti-Cancer Drugs","volume":" ","pages":"749-758"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of valproic acid and levetiracetam administration on the survival of glioma patients: a meta-analysis study.\",\"authors\":\"Arya Shirani, Mobin Obeidinia, Makan Ziafati, Javad Garavand, Moazzameh Ramezani, Fatemeh Ramezani\",\"doi\":\"10.1097/CAD.0000000000001746\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>In this meta-analysis study, the effect of valproate (VPA) and levetiracetam (LEV) on the survival of glioma patients taking temozolomide (TMZ) was investigated. The cumulative hazard ratios (HR) of overall survival (OS) and progression-free survival from published clinical studies were determined using a random effects model to estimate the strength of the association between VPA/LEV and survival in glioma patients. The results showed that VPA (data from 2304 patients from 14 clinical trial studies) and LEV (data from 1610 patients from 11 clinical trial studies) increase OS by 20% [HR = 0.80; 95% confidence interval (CI), 0.69-0.94; P = 0.01] and 18% (HR = 0.82; 95% CI, 0.68-0.98; P = 0.03), respectively. Use of VPA and LEV as anticonvulsant drugs increased the OS of patients with glioma taking TMZ to an almost equal extent. These findings need to be confirmed in larger prospective studies.</p>\",\"PeriodicalId\":7969,\"journal\":{\"name\":\"Anti-Cancer Drugs\",\"volume\":\" \",\"pages\":\"749-758\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-Cancer Drugs\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/CAD.0000000000001746\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-Cancer Drugs","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/CAD.0000000000001746","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
Effect of valproic acid and levetiracetam administration on the survival of glioma patients: a meta-analysis study.
In this meta-analysis study, the effect of valproate (VPA) and levetiracetam (LEV) on the survival of glioma patients taking temozolomide (TMZ) was investigated. The cumulative hazard ratios (HR) of overall survival (OS) and progression-free survival from published clinical studies were determined using a random effects model to estimate the strength of the association between VPA/LEV and survival in glioma patients. The results showed that VPA (data from 2304 patients from 14 clinical trial studies) and LEV (data from 1610 patients from 11 clinical trial studies) increase OS by 20% [HR = 0.80; 95% confidence interval (CI), 0.69-0.94; P = 0.01] and 18% (HR = 0.82; 95% CI, 0.68-0.98; P = 0.03), respectively. Use of VPA and LEV as anticonvulsant drugs increased the OS of patients with glioma taking TMZ to an almost equal extent. These findings need to be confirmed in larger prospective studies.
期刊介绍：
Anti-Cancer Drugs reports both clinical and experimental results related to anti-cancer drugs, and welcomes contributions on anti-cancer drug design, drug delivery, pharmacology, hormonal and biological modalities and chemotherapy evaluation. An internationally refereed journal devoted to the fast publication of innovative investigations on therapeutic agents against cancer, Anti-Cancer Drugs aims to stimulate and report research on both toxic and non-toxic anti-cancer agents. Consequently, the scope on the journal will cover both conventional cytotoxic chemotherapy and hormonal or biological response modalities such as interleukins and immunotherapy. Submitted articles undergo a preliminary review by the editor. Some articles may be returned to authors without further consideration. Those being considered for publication will undergo further assessment and peer-review by the editors and those invited to do so from a reviewer pool.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
